Compare CVS Health Corp (CVS) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs LYFT Inc — how do they compare? CVS Health Corp trades at $104.91 (market cap $135.48B), while LYFT Inc trades at $15.66 (market cap $5.93B). The key difference: CVS Health Corp is far larger — about 22.8× LYFT Inc's market cap, and CVS Health Corp pays a 2.51% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| CVS | LYFT | |
|---|---|---|
Market Cap | $135.48B | $5.93B |
Sector | Health | Industrials |
52-Week High | $106.18 | $24.57 |
52-Week Low | $58.75 | $12.65 |
Enterprise Value | $202.02B | $5.46B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Lyft trades at $15.67, up 0.38% today, with a bullish technical signal and positive cash flow trends. The stock shows attractive valuation metrics with P/E of 2.29 and P/S of 0.99, while recent earnings have been mixed with Q4 2025 beating expectations but Q1 2026 missing. Revenue growth continues with $6.32B in 2025, and the company maintains strong profitability with 43.82% net income margin. Analyst consensus is mixed with 37% buy ratings and $17.86 price target.
Lyft presents a compelling value opportunity with deep valuation discounts and improving fundamentals, though execution risks remain. The company's transition to profitability and strategic expansion into autonomous vehicles provide growth catalysts, but competitive pressures and earnings volatility require careful monitoring. The stock offers 14% upside to consensus target with manageable downside risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
